抵克力得对冠心病患者血小板聚集功能的影响及意义  

Effect of ticlopidine on platelet aggregation in patients with coronary heart disease and its significance

作　　者：于珂[1] 李洪法 

机构地区：[1]山东省聊城市人民医院,山东聊城252000 [2]冠县万善卫生院

出　　处：《心血管康复医学杂志》2005年第3期246-247,共2页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:探讨冠心病患者血小板聚集功能和抵克力得的影响。方法:选择体检正常者、不稳定心绞痛(UAP)和急性心肌梗死(AMI)患者各20例,测定三组血小板聚集功能和后两组服用抵克力得后,由二磷酸腺苷(ADP)、肾上腺素(EP)诱导的血小板聚集功能的变化。结果:UAP组和AMI组血小板聚集率明显高于对照组(P<0.001); 服抵克力得后血小板聚集率均明显降低(P<0.001)。结论:冠心病患者血小板聚集功能明显增强,抵克力得对它有明显抑制作用。Objective:To study the effect of ticlopidine on platelet aggregation in patients with coronary heart disease and its significance. Methods: The platelet aggregation function of 20 normal volunteers (control group), 20 unstable angina pectoris (UAP) patients, and 20 acute myocardial infarction (AMI) patients were studied. Results: The platelet aggregation of UAP and AMI groups increased significantly than that of control group (P<0. 001), and significantly decreased after treatment of ticlopidine (P<0. 001). Conclusion: The platelet aggregation increases in coronary heart disease patient and can be inhibited by ticlopidine.

关 键 词：血小板聚集功能 冠心病患者 抵克力得 急性心肌梗死(AMI) 二磷酸腺苷(ADP) 血小板聚集率 不稳定心绞痛 肾上腺素 抑制作用 正常者 对照组 UAP 

分 类 号：R587.1[医药卫生—内分泌] R541.4[医药卫生—内科学]